{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:18:57Z","timestamp":1791224337060,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,4,14]],"date-time":"2015-04-14T00:00:00Z","timestamp":1428969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,4,14]],"date-time":"2015-04-14T00:00:00Z","timestamp":1428969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1038\/leu.2015.95","type":"journal-article","created":{"date-parts":[[2015,5,15]],"date-time":"2015-05-15T08:44:02Z","timestamp":1431679442000},"page":"1470-1477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["NFATc1 as a therapeutic target in FLT3-ITD-positive AML"],"prefix":"10.1038","volume":"29","author":[{"given":"S K","family":"Metzelder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"von Bonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Rehberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Hessmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Inselmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Solovey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Sohlbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Stiewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Ten Haaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Ellenrieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Gattenl\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Burchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,14]]},"reference":[{"key":"BFleu201595_CR1","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/sj.leu.2400812","volume":"11","author":"S Yokota","year":"1997","unstructured":"Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997; 11: 1605\u20131609.","journal-title":"Leukemia"},{"key":"BFleu201595_CR2","first-page":"3074","volume":"93","author":"H Kiyoi","year":"1999","unstructured":"Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074\u20133080.","journal-title":"Blood"},{"key":"BFleu201595_CR3","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","volume":"99","author":"C Thiede","year":"2002","unstructured":"Thiede C, Steudel C, Mohr B, Schaich M, Sch\u00e4kel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326\u20134335.","journal-title":"Blood"},{"key":"BFleu201595_CR4","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"PD Kottaridis","year":"2001","unstructured":"Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752\u20131759.","journal-title":"Blood"},{"key":"BFleu201595_CR5","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","volume":"100","author":"S Fr\u00f6hling","year":"2002","unstructured":"Fr\u00f6hling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100: 4372\u20134380.","journal-title":"Blood"},{"key":"BFleu201595_CR6","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/sj.onc.1203354","volume":"19","author":"F Hayakawa","year":"2000","unstructured":"Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000; 19: 624\u2013631.","journal-title":"Oncogene"},{"key":"BFleu201595_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ccr.2007.08.031","volume":"12","author":"BH Lee","year":"2007","unstructured":"Lee BH, Tothova Z, Levine RL, Anderson K, Buza-Vidas N, Cullen DE et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell 2007; 12: 367\u2013380.","journal-title":"Cancer Cell"},{"key":"BFleu201595_CR8","first-page":"588","volume":"10","author":"HG Drexler","year":"1996","unstructured":"Drexler HG . Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996; 10: 588\u2013599.","journal-title":"Leukemia"},{"key":"BFleu201595_CR9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nature11016","volume":"485","author":"CC Smith","year":"2012","unstructured":"Smith CC, Wang Q, Chin C-S, Salerno S, Damon LE, Levis MJ et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012; 485: 260\u2013263.","journal-title":"Nature"},{"key":"BFleu201595_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","volume":"1","author":"E Weisberg","year":"2002","unstructured":"Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002; 1: 433\u2013443.","journal-title":"Cancer Cell"},{"key":"BFleu201595_CR11","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1182\/blood-2010-04-261867","volume":"116","author":"T Kindler","year":"2010","unstructured":"Kindler T, Lipka DB, Fischer T . FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010; 116: 5089\u20135102.","journal-title":"Blood"},{"key":"BFleu201595_CR12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2174\/138945010791320782","volume":"11","author":"KW Pratz","year":"2010","unstructured":"Pratz KW, Levis MJ . Bench to bedside targeting of FLT3 in acute leukemia. Curr Drug Targets 2010; 11: 781\u2013789.","journal-title":"Curr Drug Targets"},{"key":"BFleu201595_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/jnci\/djm328","volume":"100","author":"W Zhang","year":"2008","unstructured":"Zhang W, Konopleva M, Shi Y-X, McQueen T, Harris D, Ling X et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008; 100: 184\u2013198.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu201595_CR14","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.1182\/blood-2009-03-208298","volume":"113","author":"S Metzelder","year":"2009","unstructured":"Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009; 113: 6567\u20136571.","journal-title":"Blood"},{"key":"BFleu201595_CR15","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1038\/leu.2012.105","volume":"26","author":"SK Metzelder","year":"2012","unstructured":"Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, G\u00f6tze K et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 2012; 26: 2353\u20132359.","journal-title":"Leukemia"},{"key":"BFleu201595_CR16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/jnci\/djr107","volume":"103","author":"S Hu","year":"2011","unstructured":"Hu S, Niu H, Inaba H, Orwick S, Rose C, Panetta JC et al. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst 2011; 103: 893\u2013905.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu201595_CR17","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/leu.2014.54","volume":"28","author":"F Ravandi","year":"2014","unstructured":"Ravandi F, Arana YiC, Cortes JE, Levis M, Faderl S, Garcia-Manero G et al. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia 2014; 28: 1543\u20131545.","journal-title":"Leukemia"},{"key":"BFleu201595_CR18","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1182\/blood-2013-01-480228","volume":"121","author":"F Ravandi","year":"2013","unstructured":"Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013; 121: 4655\u20134662.","journal-title":"Blood"},{"key":"BFleu201595_CR19","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","volume":"114","author":"PP Zarrinkar","year":"2009","unstructured":"Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009; 114: 2984\u20132992.","journal-title":"Blood"},{"key":"BFleu201595_CR20","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1200\/JCO.2013.48.8783","volume":"31","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol 2013; 31: 3681\u20133687.","journal-title":"J Clin Oncol"},{"key":"BFleu201595_CR21","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.1182\/blood-2011-06-363960","volume":"119","author":"CH Man","year":"2012","unstructured":"Man CH, Fung TK, Ho C, Han HHC, Chow HCH, Ma ACH et al. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood 2012; 119: 5133\u20135143.","journal-title":"Blood"},{"key":"BFleu201595_CR22","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1158\/1078-0432.CCR-13-1323","volume":"19","author":"SD Baker","year":"2013","unstructured":"Baker SD, Zimmerman EI, Wang Y-D, Orwick S, Zatechka DS, Buaboonnam J et al. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Clin Cancer Res 2013; 19: 5758\u20135768.","journal-title":"Clin Cancer Res"},{"key":"BFleu201595_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1182\/blood-2005-06-2469","volume":"107","author":"F Heidel","year":"2006","unstructured":"Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 2006; 107: 293\u2013300.","journal-title":"Blood"},{"key":"BFleu201595_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1182\/blood-2003-06-1969","volume":"103","author":"R Zheng","year":"2004","unstructured":"Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, Gorin NC et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood 2004; 103: 267\u2013274.","journal-title":"Blood"},{"key":"BFleu201595_CR25","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1182\/blood-2009-09-242859","volume":"115","author":"KW Pratz","year":"2010","unstructured":"Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M . FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010; 115: 1425\u20131432.","journal-title":"Blood"},{"key":"BFleu201595_CR26","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2009-03-209999","volume":"114","author":"S Kayser","year":"2009","unstructured":"Kayser S, Schlenk RF, Londono MC, Breitenbuecher F, Wittke K, Du J et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 2009; 114: 2386\u20132392.","journal-title":"Blood"},{"key":"BFleu201595_CR27","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s12185-013-1334-8","volume":"97","author":"MR Grunwald","year":"2013","unstructured":"Grunwald MR, Levis MJ . FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol 2013; 97: 683\u2013694.","journal-title":"Int J Hematol"},{"key":"BFleu201595_CR28","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nri1632","volume":"5","author":"F Macian","year":"2005","unstructured":"Macian F . NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 2005; 5: 472\u2013484.","journal-title":"Nat Rev Immunol"},{"key":"BFleu201595_CR29","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nri2818","volume":"10","author":"MR M\u00fcller","year":"2010","unstructured":"M\u00fcller MR, Rao A . NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol 2010; 10: 645\u2013656.","journal-title":"Nat Rev Immunol"},{"key":"BFleu201595_CR30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/369497a0","volume":"369","author":"JP Northrop","year":"1994","unstructured":"Northrop JP, Ho SN, Chen L, Thomas DJ, Timmerman LA, Nolan GP et al. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature 1994; 369: 497\u2013502.","journal-title":"Nature"},{"key":"BFleu201595_CR31","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/365352a0","volume":"365","author":"J Jain","year":"1993","unstructured":"Jain J, McCaffrey PG, Miner Z, Kerppola TK, Lambert JN, Verdine GL et al. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 1993; 365: 352\u2013355.","journal-title":"Nature"},{"key":"BFleu201595_CR32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/357695a0","volume":"357","author":"NA Clipstone","year":"1992","unstructured":"Clipstone NA, Crabtree GR . Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992; 357: 695\u2013697.","journal-title":"Nature"},{"key":"BFleu201595_CR33","doi-asserted-by":"publisher","first-page":"367S","DOI":"10.1016\/j.transproceed.2004.01.043","volume":"36","author":"WJ Hogan","year":"2004","unstructured":"Hogan WJ, Storb R . Use of cyclosporine in hematopoietic cell transplantation. Transplant Proc 2004; 36: 367S\u2013371S.","journal-title":"Transplant Proc"},{"key":"BFleu201595_CR34","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/nrc2735","volume":"9","author":"M Mancini","year":"2009","unstructured":"Mancini M, Toker A . NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer 2009; 9: 810\u2013820.","journal-title":"Nat Rev Cancer"},{"key":"BFleu201595_CR35","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1038\/sj.emboj.7601246","volume":"25","author":"M Buchholz","year":"2006","unstructured":"Buchholz M, Schatz A, Wagner M, Michl P, Linhart T, Adler G et al. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+\/calcineurin signaling pathway. EMBO J 2006; 25: 3714\u20133724.","journal-title":"EMBO J"},{"key":"BFleu201595_CR36","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1158\/2159-8290.CD-13-0593","volume":"4","author":"S Baumgart","year":"2014","unstructured":"Baumgart S, Chen N-M, Siveke JT, K\u00f6nig A, Zhang J-S, Singh SK et al. Inflammation-Induced NFATc1-STAT3 Transcription Complex Promotes Pancreatic Cancer Initiation by KrasG12D. Cancer Discov 2014; 4: 688\u2013701.","journal-title":"Cancer Discov"},{"key":"BFleu201595_CR37","doi-asserted-by":"publisher","first-page":"28761","DOI":"10.1074\/jbc.M110.197533","volume":"286","author":"SK Singh","year":"2011","unstructured":"Singh SK, Baumgart S, Singh G, K\u00f6nig AO, Reutlinger K, Hofbauer LC et al. Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid. J Biol Chem 2011; 286: 28761\u201328771.","journal-title":"J Biol Chem"},{"key":"BFleu201595_CR38","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.exphem.2007.02.001","volume":"35","author":"A Kiani","year":"2007","unstructured":"Kiani A, Kuithan H, Kuithan F, Kytt\u00e4l\u00e4 S, Habermann I, Temme A et al. Expression analysis of nuclear factor of activated T cells (NFAT) during myeloid differentiation of CD34+ cells: regulation of Fas ligand gene expression in megakaryocytes. Exp Hematol 2007; 35: 757\u2013770.","journal-title":"Exp Hematol"},{"key":"BFleu201595_CR39","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1189\/jlb.0404259","volume":"76","author":"A Kiani","year":"2004","unstructured":"Kiani A, Habermann I, Haase M, Feldmann S, Boxberger S, Sanchez-Fernandez MA et al. Expression and regulation of NFAT (nuclear factors of activated T cells) in human CD34+ cells: down-regulation upon myeloid differentiation. J Leukoc Biol 2004; 76: 1057\u20131065.","journal-title":"J Leukoc Biol"},{"key":"BFleu201595_CR40","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1365-2141.2004.05313.x","volume":"128","author":"T Marafioti","year":"2005","unstructured":"Marafioti T, Marafiot T, Pozzobon M, Hansmann M-L, Ventura R, Pileri SA et al. The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas. Br J Haematol 2005; 128: 333\u2013342.","journal-title":"Br J Haematol"},{"key":"BFleu201595_CR41","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2005-03-1167","volume":"106","author":"LV Pham","year":"2005","unstructured":"Pham LV, Tamayo AT, Yoshimura LC, Lin-Lee Y-C, Ford RJ . Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood 2005; 106: 3940\u20133947.","journal-title":"Blood"},{"key":"BFleu201595_CR42","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nm1588","volume":"13","author":"H Medyouf","year":"2007","unstructured":"Medyouf H, Alcalde H, Berthier C, Guillemin MC, Santos dos NR, Janin A et al. Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia. Nat Med 2007; 13: 736\u2013741.","journal-title":"Nat Med"},{"key":"BFleu201595_CR43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","volume":"18","author":"MA Gregory","year":"2010","unstructured":"Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T et al. Wnt\/Ca2+\/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 2010; 18: 74\u201387.","journal-title":"Cancer Cell"},{"key":"BFleu201595_CR44","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","volume":"19","author":"A Burchert","year":"2005","unstructured":"Burchert A, Wang Y, Cai D, Bubnoff von N, Paschka P, M\u00fcller-Br\u00fcsselbach S et al. Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development. Leukemia 2005; 19: 1774\u20131782.","journal-title":"Leukemia"},{"key":"BFleu201595_CR45","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","volume":"109","author":"Y Wang","year":"2007","unstructured":"Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation. Blood 2007; 109: 2147\u20132155.","journal-title":"Blood"},{"key":"BFleu201595_CR46","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2010-08-303495","volume":"119","author":"A Kumari","year":"2012","unstructured":"Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A . Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 2012; 119: 530\u2013539.","journal-title":"Blood"},{"key":"BFleu201595_CR47","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.4049\/jimmunol.168.10.4936","volume":"168","author":"CM Porter","year":"2002","unstructured":"Porter CM, Clipstone NA . Sustained NFAT signaling promotes a Th1-like pattern of gene expression in primary murine CD4+ T cells. J Immunol 2002; 168: 4936\u20134945.","journal-title":"J Immunol"},{"key":"BFleu201595_CR48","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"T-C Chou","year":"2006","unstructured":"Chou T-C . Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621\u2013681.","journal-title":"Pharmacol Rev"},{"key":"BFleu201595_CR49","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/352803a0","volume":"352","author":"WM Flanagan","year":"1991","unstructured":"Flanagan WM, Corth\u00e9sy B, Bram RJ, Crabtree GR . Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991; 352: 803\u2013807.","journal-title":"Nature"},{"key":"BFleu201595_CR50","doi-asserted-by":"publisher","first-page":"20653","DOI":"10.1074\/jbc.270.35.20653","volume":"270","author":"J Park","year":"1995","unstructured":"Park J, Yaseen NR, Hogan PG, Rao A, Sharma S . Phosphorylation of the transcription factor NFATp inhibits its DNA binding activity in cyclosporin A-treated human B and T cells. J Biol Chem 1995; 270: 20653\u201320659.","journal-title":"J Biol Chem"},{"key":"BFleu201595_CR51","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1126\/science.285.5436.2129","volume":"285","author":"J Aramburu","year":"1999","unstructured":"Aramburu J, Yaffe MB, L\u00f3pez-Rodr\u00edguez C, Cantley LC, Hogan PG, Rao A . Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 1999; 285: 2129\u20132133.","journal-title":"Science"},{"key":"BFleu201595_CR52","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature11814","volume":"494","author":"M Thakur Das","year":"2013","unstructured":"Thakur Das M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494: 251\u2013255.","journal-title":"Nature"},{"key":"BFleu201595_CR53","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1182\/blood.V98.4.988","volume":"98","author":"ML Linenberger","year":"2001","unstructured":"Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001; 98: 988\u2013994.","journal-title":"Blood"},{"key":"BFleu201595_CR54","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1182\/blood-2003-02-0396","volume":"102","author":"RB Walter","year":"2003","unstructured":"Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML . Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003; 102: 1466\u20131473.","journal-title":"Blood"},{"key":"BFleu201595_CR55","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","volume":"28","author":"T Fischer","year":"2010","unstructured":"Fischer T, Stone RM, DeAngelo DJ, Galinsky I, Estey E, Lanza C et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010; 28: 4339\u20134345.","journal-title":"J Clin Oncol"},{"key":"BFleu201595_CR56","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/leu.2010.132","volume":"24","author":"KW Pratz","year":"2010","unstructured":"Pratz KW, Cho E, Levis MJ, Karp JE, Gore SD, McDevitt M et al. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia 2010; 24: 1437\u20131444.","journal-title":"Leukemia"},{"key":"BFleu201595_CR57","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/ijc.2910450210","volume":"45","author":"K Nooter","year":"1990","unstructured":"Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T, Valerio D . Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int J Cancer 1990; 45: 263\u2013268.","journal-title":"Int J Cancer"},{"key":"BFleu201595_CR58","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1182\/blood.V98.12.3212","volume":"98","author":"AF List","year":"2001","unstructured":"List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001; 98: 3212\u20133220.","journal-title":"Blood"},{"key":"BFleu201595_CR59","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele W, Stegner HE . Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8: 138\u2013140.","journal-title":"Pathologe"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201595.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201595","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201595.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:19:27Z","timestamp":1648743567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,14]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["BFleu201595"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.95","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,14]]},"assertion":[{"value":"9 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AB received funding from Bayer Healthcare in support of the SORMAIN trial, which is testing sorafenib maintenance therapy after allogeneic stem cell transplantation in FLT3-ITD+ AML (EudraCT 2010-018539-16). The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}